DAIC

JULY 25, 2024

FDA granted CardiAMP Cell Therapy a Breakthrough Device Designation for the treatment of ischemic heart failure. Leslie Miller, MD , trial investigator at the CHF Heart Function Clinic at BayCare Morton Plant Hospital in Clearwater, Florida and a member of the CardiAMP Heart Failure II Study Executive Steering Committee. “As

Heart Failure 111

Heart Failure Quality of Life CMS Reimbursement 111

DAIC

APRIL 18, 2024

Inhibiting the function of this protein, which is linked to congestive heart failure (CHF), could potentially lead to a therapeutic effect on the heart.1,2 Inhibiting the function of this protein, which is linked to congestive heart failure (CHF), could potentially lead to a therapeutic effect on the heart.1,2

Heart Failure 105

Heart Failure Public Health Cardiac Function Research 105

Frontiers in Cardiovascular Medicine

MARCH 5, 2025

The aim of this study is to describe the literature on the relationship between motor-cognitive DTT and cognitive performance (CP) in individuals with coronary artery disease (CAD) and/or heart failure (HF).MethodThis Searches were performed in the MEDLINE/Pubmed, Scielo, Lilacs, PEDro, and EMBASE databases.

Coronary Artery Disease 52

Coronary Artery Disease Heart Failure Cardiac Rehabilitation Article 52

DAIC

JANUARY 22, 2024

(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG , announced that it is initiating GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase 2 trial of AB-1002 (also known as NAN-101 ) for the treatment of congestive heart failure (CHF). Heart failure. Published 2022.

Heart Failure 105

Heart Failure Public Health Cardiomyopathy 105

DAIC

FEBRUARY 6, 2024

Matthew Segar co-authored a study in JACC Heart Failure led by his research and residency mentor, University of Texas Southwestern Medical Center's Dr. Ambarish Pandey , that utilized a machine learning-based-approach to identify, understand, and predict diuretic responsiveness in patients with acute decompensated heart failure (ADHF).

Heart Failure 111

Heart Failure Research Hospital Cardiovascular Disease 111

DAIC

MAY 6, 2024

Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

DAIC

FEBRUARY 12, 2024

Barostim is the world’s first FDA-approved neuromodulation heart failure device, which works by stimulating baroreceptors — natural sensors located in the wall of the carotid artery, according to CVRx. In November, 2022, the company launched its new Barostim NEO2 IPG. and Allina Health. and Allina Health. and Allina Health.

Heart Failure 104

Heart Failure Hospital Quality of Life Heart Attack 104

CardiacWire

FEBRUARY 12, 2025

Anthos subsequently kicked off three phase 3 trials in 2022, and wrapping up these studies by 2026 will now be Novartis responsibility. Besides the hefty price tag , the re-acquisition puts Novartis back into competition with other big-name Factor XI inhibitor developers, whove faced a series of setbacks.

AFIB 102

AFIB Embolism Plaque Stroke 102

DAIC

FEBRUARY 22, 2024

The study, which is testing a novel rehabilitation program designed for older patients hospitalized with acute heart failure, is funded by a five-year, $30 million grant , awarded to Wake Forest University School of Medicine in 2022 by the National Institute of Aging, part of the National Institutes of Health.

Heart Failure 105

Heart Failure Research Preserved Ejection Fraction Hospital 105

CardiacWire

APRIL 21, 2024

A BMJ study out of Denmark provided alarming new insights into atrial fibrillation’s impact on patients’ future cardiovascular health, while highlighting the need to improve post-AFib heart failure and stroke prevention. The researchers analyzed 2000-2022 data from 3.5M in 2011-2022. overall, increasing from 24.2%

AFIB 105

AFIB Heart Failure Myocardial Infarction Stroke 105

American College of Cardiology

OCTOBER 1, 2024

Guideline-directed medical therapy (GDMT) is essential for managing heart failure with reduced ejection fraction (HFrEF).

Heart Failure 61

Heart Failure Quality of Life Article 61

European Journal of Heart Failure

OCTOBER 30, 2023

Integration of palliative care in the 2021 ESC and the 2022 AHA/ACC/HFSA heart failure guidelines. ACC, American College of Cardiology; AHA, American Heart Association; ESC, European Society of Cardiology; HF, heart failure; HFSA, Heart Failure Society of America; LD, limited; R, randomized.

Heart Failure 40

Heart Failure Article 40

European Journal of Heart Failure

MARCH 30, 2025

Heart failure with reduced ejection fraction (HFrEF) survey endorsed by the Council for Cardiology Practice and the Heart Failure Association of the European Society of Cardiology (ESC). Methods and results A 22-question survey regarding the diagnosis and treatment of HFrEF was delivered between March and June 2022.

Heart Failure 40

Heart Failure Academic Research Article 40

Circulation: Heart Failure

DECEMBER 13, 2023

Circulation: Heart Failure, Ahead of Print.

Heart Failure 40

Heart Failure Circulation 40

Frontiers in Cardiovascular Medicine

OCTOBER 10, 2024

ObjectiveTo investigate the therapeutic effect of Vericiguat combined with “new quadruple” drugs on patients with heart failure (HF).MethodsFrom ConclusionVericiguat combined with the “new quadruple” therapy has a significant therapeutic effect on patients with heart failure caused by MI, DCM or VHD.

Heart Failure 52

Heart Failure Preserved Ejection Fraction Cardiac Function Quality of Life 52

DAIC

JUNE 24, 2024

Kittleson, director of Heart Failure Research and director of Post Graduate Medical Education in Heart Failure and Transplantation, is an associate editor specializing in heart failure. Levine Early Career Clinical Investigator Award from the American Heart Association.

Heart Failure 100

Heart Failure Transplant Interventional Cardiology Research 100

Frontiers in Cardiovascular Medicine

MAY 13, 2024

AimsTo assess the barriers to guideline-directed medical therapy (GDMT) use in heart failure (HF), diagnostic workup and general knowledge about HF among physicians in Sweden.MethodsA survey about the management of HF was sent to 828 Swedish physicians including general practitioners (GPs) and specialists during 2021–2022.

Heart Failure 52

Heart Failure Nursing Outpatient Education 52

Dr. S. Venkatesan MD

OCTOBER 11, 2024

However, advanced heart failure therapy never means it can be achieved only by state-of-the-art technology. Cardiac failure management remains basically disciplined medical management and a holistic approach to improve the quality of life. Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure.

Heart Failure 59

Heart Failure Anatomy Ultrasound Technology 59

Journal of the American Heart Association

MARCH 7, 2025

Journal of the American Heart Association, Ahead of Print. BackgroundTelemedicine interventions (TMIs) for heart failure (HF) can reduce hospitalizations and deaths. It is unclear if low literacy and limited access to technology in low and middleincome countries affect these benefits.

Heart Failure 45

Heart Failure Hospital Education Blood Pressure 45

Circulation: Heart Failure

FEBRUARY 28, 2025

Circulation: Heart Failure, Ahead of Print. High out-of-pocket costs and financial toxicity related to heart failure treatment are substantial concerns. Two of 4 pillars of guideline-directed medical therapy for heart failure with reduced ejection fraction, for example, carry high costs that may attenuate their uptake.

Heart Failure 40

Heart Failure Circulation 40

Journal of the American Heart Association

DECEMBER 14, 2024

Journal of the American Heart Association, Volume 13, Issue 24 , December 17, 2024. EAT volume and extracellular volume were calculated using cardiovascular magnetic resonance. The main outcome was the composite of allcause mortality and first HF hospitalization.

Preserved Ejection Fraction 58

Preserved Ejection Fraction Heart Failure Hospital Outcomes 58

Frontiers in Cardiovascular Medicine

JANUARY 28, 2024

Sacubitril/valsartan can improve outcomes for patients with heart failure and ventricular tachycardia, but few studies examined whether it can reduce recurrence or improve cardiovascular outcomes in patients with persistent atrial fibrillation after catheter ablation.

Atrial Fibrillation 64

Atrial Fibrillation Heart Failure Ablation Electrocardiogram 64

American College of Cardiology

AUGUST 8, 2024

A newly released ACC Expert Consensus Decision Pathway (ECDP) focused on the clinical assessment, management and trajectory of patients hospitalized with heart failure (HF) includes revisions to the 2019 version of the document and harmonizes guidance in response to the ACC/AHA Heart Failure Guideline released in 2022.

Heart Failure 65

Heart Failure Document Hospital Article 65

Open Heart

APRIL 24, 2024

Introduction Heart failure (HF) incidence is increasing in older adults with high hospitalisation and mortality rates. Results Data were collected in April 2012 to January 2014 and in June 2021 to December 2022. Treatment is complicated by side effects and comorbidities. Statistical significance is determined at p<0.05.

Heart Failure 52

Heart Failure Preserved Ejection Fraction ACE Inhibitor Pharmacology 52

Dr. Paddy Barrett

NOVEMBER 1, 2024

Death from heart disease: 51% reduction in risk. Heart Failure: 69% reduction in risk. 2022 Mar 3;11(5):872. Death from any cause: 53% reduction in risk. Cancer deaths: 43% reduction in risk. High Blood Pressure: 37% reduction in risk. Dementia: 64% reduction in risk. Kidney Disease: 42% reduction in risk.

Exercise 119

Exercise Heart Disease Quality of Life Blood Pressure 119

The British Journal of Cardiology

AUGUST 6, 2024

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to reduce cardiovascular rehospitalisation in heart failure with reduced ejection fraction (HFrEF) patients. A retrospective study of four hospitals in England involving 184 patients with HFrEF exacerbations between March 2021 and June 2022 was performed.

Inpatient 40

Inpatient Heart Failure Diabetes Hospital 40

Circulation

NOVEMBER 11, 2024

Introduction:It is estimated that about 30% of patients with heart failure (HF) have iron deficiency anemia that can be masked as chronic normocytic anemia or functional anemia. Currently, the ACC/AHA 2022 heart failure guidelines give IV Iron replacement a Class IIa recommendation. However, only 18.8%

Heart Failure 40

Heart Failure Education Patient Care Circulation 40

DAIC

FEBRUARY 12, 2024

A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. In November, 2022, the company launched its new Barostim NEO2 IPG. and Allina Health.

Heart Failure 52

Heart Failure Hospital Quality of Life Heart Attack 52

European Journal of Heart Failure

DECEMBER 18, 2024

KCCQ-12, 12-question Kansas City Cardiomyopathy Questionnaire; NT-proBNP, N-terminal pro-B-type natriuretic peptide Abstract Aims We sought to characterize the clinical course of patients following worsening heart failure (WHF) treated in an outpatient setting and to identify factors associated with a poor response to standard of care with loop diuretics. (..)

Outpatient 40

Outpatient Heart Failure Cardiomyopathy Research 40

Journal of the American Heart Association

JANUARY 9, 2024

Journal of the American Heart Association, Ahead of Print. BackgroundSoluble suppression of tumorigenicity‐2 (sST2) predicts mortality in patients with heart failure. P=0.01) for right heart failure, both per 10‐unit sST2 increase. P=0.05), whereas the HR of right heart failure was not significant (1.22 [95% CI, 0.94–1.59];P=0.14),

Heart Failure 45

Heart Failure Research Outcomes 45

European Journal of Heart Failure

OCTOBER 30, 2023

Prediction models for risk of incident heart failure in the community demonstrated excellent prediction performance but their usefulness in clinical practice remains uncertain. Aims Multivariable prediction models can be used to estimate risk of incident heart failure (HF) in the general population.

Heart Failure 40

Heart Failure Atherosclerosis Research Article 40

DAIC

JANUARY 15, 2024

Cardiac amyloidosis is a heterogeneous disease that results from the accumulation of abnormal proteins within the heart, impairing its ability to pump blood. Over time, the build-up of these proteins causes the heart muscle to stiffen, eventually leading to heart failure, which can have dire outcomes if not found early.

Ultrasound 119

Ultrasound Coronary Artery Disease Innovation Heart Failure 119

Circulation

NOVEMBER 11, 2024

Introduction:Adequate heart failure (HF) self-management is crucial for alleviating distressing symptoms. Circulation, Volume 150, Issue Suppl_1 , Page A4137716-A4137716, November 12, 2024. While disease knowledge is important, it is insufficient for sustained self-care.

Heart Failure 40

Heart Failure Nursing Circulation Research 40

European Journal of Heart Failure

DECEMBER 13, 2023

Abstract Aims There is uncertainty about the definition of iron deficiency (ID) and the association between ID and prognosis in patients with advanced heart failure. We evaluated three definitions of ID in patients referred for heart transplantation. The same association was not seen with guideline definition of ID.

Heart Failure 40

Heart Failure Heart Transplant Transplant Tricuspid 40

European Journal of Heart Failure

NOVEMBER 24, 2023

The different risk of new-onset, chronic, worsening, and advanced heart failure. CI, confidence interval; HF, heart failure; OR, odds ratio. Abstract Aims Heart failure (HF) is a chronic and progressive syndrome associated with a poor prognosis.

Heart Failure 40

Heart Failure Hospital Outcomes Research 40

DAIC

JULY 17, 2024

million in 2022, with the global market estimated to expand at a Compound Annual Growth Rate of 7.3%, reaching $2.1 Worldwide revenue from the transseptal access systems market was $941.3 billion by the end of 2033.

Myocardial Infarction 105

Myocardial Infarction Atrial Fibrillation Technology Angina 105

Journal of the American Heart Association

FEBRUARY 8, 2025

However, it is unclear whether GLP1RA is effective compared with DPP4i in patients with heart failure (HF) with type 2 diabetes (T2D). Primary outcome was 12month incidence of allcause death. Secondary outcome was hospitalization.

Heart Failure 45

Heart Failure Diabetes Outcomes Hospital 45